ADMAADMA Biologics, Inc.
$10.36-35% 1Y
$10.36
$7.6052 weeks$20.38
ADMA in its own filings
ADMA's filing record carries 2 kinds of hard flag, each is shown beside the share of the whole market carrying the same one, because more than half of all companies carry at least one.
427
Events found in the filings · across 995 filings · the record starts in 2006
- Hard flags
- 2
Hard flags
- Most recent filing
- Aug 5, 2026
Most recent filing · Form 10-Q
- Record starts
- Sep 8, 2006
Record starts · the earliest filing Ryufin holds for this name
Details›
- Next results filingsame week as a year ago
- expected around Nov 4, 2026
- Change in certifying accountant6 occurrences
- 2024-10-31
- Late periodic reportpast_3y
- 2025-03-03
- Security removed from listing or deregistered2 occurrences · usually a matured note or preferred class, not the common shares
- 2022-06-16
- SEC comment-letter activity45 occurrences
- 2025-09-29
SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 5, 2026ADMA Biologics Reports Second Quarter 2026 Financial Results and Provides Business Update.Earnings release · press release
- May 6, 2026ADMA Biologics Reports First Quarter 2026 Financial Results and Provides Business Update.Earnings release · press release
- May 4, 2026On May 4, 2026, ADMA Biologics, Inc. (the “Company”) issued a press release announcing that the U.S. Food and Drug Administration has approved the Company’s label expansion supplemental Biologics License Application for ASCENIV TM to include pediatric immune compromised patients two years of age and older.Other event · Form 8-K
- Mar 27, 2026ADMA Biologics Issues Statement Refuting Unsubstantiated, Misleading and Inaccurate Allegations by Culper Research.Regulation FD disclosure · press release
- Mar 2, 2026On March 2, 2026, the Company entered into an accelerated share repurchase agreement (the “ASR Agreement”) with JPMorgan Chase Bank, National Association (“JPMorgan”) to repurchase $125 million of shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), as part of the Company’s …Regulation FD disclosure · Form 8-K
- Feb 25, 2026Tade Retirement; CFO Transition On February 20, 2026, Brad Tade notified the Company that he is retiring from his position as Chief Financial Officer and Treasurer of the Company effective at the close of business on February 25, 2026, following the filing of the Company’s Annual Report on Form 10-K for the year ended …Earnings release · Form 8-K
- Jan 12, 2026ADMA Biologics Announces Preliminary Full Year 2025 Unaudited Total Revenue and Provides Business Update.Earnings release · press release
- Nov 5, 2025ADMA Biologics Announces Third Quarter 2025 Financial Results and Provides Business Update.Earnings release · press release
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
opening the record…